Pinealon
EDR peptide / Glu-Asp-Arg
Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.
Mécanisme d'action
Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual administration may improve bioavailability. Cycles repeated every 3-6 months.
Notes de recherche
Clinical Research Status
Pinealon has been studied primarily in Russian clinical research settings, with publications appearing in Russian biomedical journals and the St. Petersburg Institute of Bioregulation and Gerontology. Clinical studies in elderly patients have reported improvements in sleep quality, cognitive function, and normalization of melatonin cycling following oral or intranasal administration. It is registered and available as a dietary supplement in Russia but has not undergone Western regulatory review or FDA evaluation.
Key Published Findings
Research by Khavinson's group demonstrates that Pinealon can penetrate cell membranes and nuclear envelopes to interact with specific DNA sequences, potentially regulating gene expression related to pineal gland function. In vitro studies show the peptide promotes neuronal survival under oxidative stress conditions and normalizes circadian gene expression patterns. Animal studies indicate restoration of melatonin synthesis capacity in aged rats and improvement of learning and memory in models of accelerated aging.
Safety Profile
As a naturally occurring amino acid sequence found in human tissue, Pinealon is reported to have an excellent safety profile with no documented adverse effects in available clinical literature. The tripeptide structure is rapidly metabolized into constituent amino acids (glutamic acid, aspartic acid, arginine), minimizing accumulation risk. No drug interactions have been formally documented, though caution is theoretically warranted when combining with exogenous melatonin or other sleep-modulating compounds.
Comparison to Related Compounds
Pinealon differs from exogenous melatonin supplementation by theoretically restoring endogenous melatonin production capacity rather than simply replacing the hormone. Compared to the related Khavinson peptide Epithalon (which targets telomerase in the pineal gland), Pinealon focuses on functional normalization rather than cellular longevity mechanisms. Within the bioregulator peptide family, each compound is tissue-specific: Pinealon targets the pineal gland, Cortexin targets the brain cortex, and Retinalamin targets the retina.
Community Observations
Users typically report improved sleep onset latency and sleep quality within 1-2 weeks of sublingual or intranasal administration. Some users prefer Pinealon over exogenous melatonin due to the absence of morning grogginess and more natural-feeling sleep architecture. Sourcing is primarily limited to Russian pharmacies or specialized peptide suppliers, with quality verification being a common concern in the community.
Moitié de vie
~15-30 minutes
Réconstitution
N/A (typically oral/sublingual capsule)
Conservation
Lyophilisé
Room temperature. Protect from moisture.
Réconstitué
N/A (oral form)
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Pinealon ?
Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.
Comment agit Pinealon ?
Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.
Quel est le statut réglementaire de Pinealon aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de Pinealon ?
~15-30 minutes
Sous quels autres noms Pinealon est-il connu ?
EDR peptide, Glu-Asp-Arg
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète